|
Crohn Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In healthy ileal mucosa, patients with CD showed a pattern identical to normal controls with main expression of MUC2 and MUC3, lesser expression of MUC1 and MUC4, and no expression of MUC5AC, MUC5B, MUC6, or MUC7.
|
11559653 |
2001 |
|
Barrett Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Barrett's oesophagus strongly expressed MUC5AC and MUC3 in the superficial columnar epithelium, MUC2 in the goblet cells, and MUC6 in the glands.
|
11076872 |
2000 |
|
Liver calculus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The markedly proliferated intramural and extramural peribiliary glands in hepatolithiasis frequently expressed MUC3 and MUC6 apomucins and focally expressed MUC2 and MUC5 apomucins.
|
9425917 |
1998 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additional investigation of MUC3 and MUC4 in ovarian cancers may lead to new approaches for early detection and therapy.
|
9850092 |
1998 |
|
Inflammatory Bowel Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The constitutive expression of MUC2 and MUC3 mRNA in inflammatory bowel diseases suggests that these genes may be necessary for maintenance of normal epithelial cell function during inflammation.
|
8813081 |
1996 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, mucin-core-peptide-specific antibodies and cDNA probes were used to determine the relative expression of mucin genes corresponding to one membrane-bound mucin (MUC1), two intestinal mucins (MUC2 and MUC3), and one tracheobronchial mucin (MUC4) in normal (nonneoplastic) lung, and in lung neoplasms.
|
8638091 |
1996 |
|
Adenomatous Polyps
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that enhanced immunoreactivity of MUC1, MUC2 and MUC3 mucin tandem repeats occurs in adenomatous polyps and is associated with an increased risk for malignant transformation.
|
8859775 |
1996 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer.
|
8638091 |
1996 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer.
|
8638091 |
1996 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer.
|
8638091 |
1996 |
|
Malignant transformation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
We conclude that enhanced immunoreactivity of MUC1, MUC2 and MUC3 mucin tandem repeats occurs in adenomatous polyps and is associated with an increased risk for malignant transformation.
|
8859775 |
1996 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specific mucin gene expression was determined using cDNA probes for 2 distinct intestinal mucins (MUC-2 and MUC-3) and one breast cancer mucin (MUC-1).
|
8443822 |
1993 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specific mucin gene expression was determined using cDNA probes for 2 distinct intestinal mucins (MUC-2 and MUC-3) and one breast cancer mucin (MUC-1).
|
8443822 |
1993 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gain- and loss-of-function assays showed that MUC17 inhibited the H. pylori-enhanced GC cell growth by preventing the translocation of H. pylori CagA into GC cells.
|
30778796 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MUC17 thus inactivated NFκB to inhibit GC cell proliferation in response to pro-inflammatory cytokines.
|
31262330 |
2019 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in >20% of the carcinomas.
|
29575536 |
2018 |
|
Hyperplastic Polyp
|
0.020 |
Biomarker
|
disease |
BEFREE |
Improved diagnostic potential was revealed by multivariate logistic regression analysis where combinatorial panel of MUC5AC/MUC17 discriminated SSA/P from HP (SN/SP=85/82%).
|
27705923 |
2017 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Marked increased expression of MUC17, the cell junction protein genes VSIG1 and GJB5, and the antiapoptotic gene REG4 were found in SSA/Ps, relative to controls and adenomas, were verified by qPCR analysis of additional SSA/Ps (n = 21) and adenomas (n = 10).
|
24533081 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the kidney, MUC3 is expressed in normal convoluted tubules and in renal clear cell carcinoma.
|
14550470 |
2003 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These findings suggest the implication of MUC3 in renal carcinogenesis.
|
14550470 |
2003 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
MUC1, MUC3 and MUC6 were expressed both in normal kidney and in renal carcinomas.
|
12010365 |
2002 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In renal carcinoma, we showed a heterogeneous expression of MUC1 and MUC3 with an over-expression of MUC3 in renal clear cell carcinoma.
|
12010365 |
2002 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
The over-expression of MUC3 in renal cell carcinomas favours its implication in renal tumorigenesis.
|
12010365 |
2002 |